<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121152">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076971</url>
  </required_header>
  <id_info>
    <org_study_id>FUN-CMV-2013-01</org_study_id>
    <nct_id>NCT02076971</nct_id>
  </id_info>
  <brief_title>Evaluate Cytomegalovirus (CMV)-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients With CMV-positive Serology (R+) Prior to Transplant and Its Involvement in the Development of CMV Infection</brief_title>
  <acronym>REIVI</acronym>
  <official_title>A Multicenter Prospective Observational Study to Evaluate Cytomegalovirus (CMV)-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients With CMV-positive Serology (R+) Prior to Transplant and Its Involvement in the Development of CMV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Catalana de Pneumologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Farma, S.A</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Catalana de Pneumologia</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the sensitivity and specificity of QuantiFeron®
      and ImmuKnow® in combination for early detection of patients who will develop CMV infection
      in lung transplant patients with CMV-positive serology (R+) prior to transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of the study are:

        -  To evaluate Cytomegalovirus (CMV)-specific immune response measured by QuantiFeron®.

        -  To evaluate overall immune response measured by ImmuKnow®.

        -  To study the course of QuantiFeron® and ImmunKnow®over the follow-up period.

        -  To correlate levels of ImmuKnow® and QuantiFeron®.

        -  To evaluate the relationship between levels and doses of immunosuppressants and their
           relationship to degree of overall immunosuppression (ImmuKnow®).

        -  To evaluate the relationship between infections, immunological complications and degree
           of overall immunosuppression (ImmuKnow®).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quantification of interferon-γ produced by specific CD8+ T cells after ex-vivo stimulation with various CMV epitopes using the commercial assay QuantiFeron®- CMV</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantiferon® is assessed multiple times and it will be considered positive when first positive test is assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of overall immune response by determination of the activity of CD4+ T cells</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>InmunKnow® is assessed multiple times and it will be considered positive when first positive test is assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of CMV viral replication in blood measured by PCR</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>PCR is assessed multiple times and it will be considered positive when first positive test is assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of immunosuppressive drugs: Blood levels of calcineurin inhibitors (tacrolimus or cyclosporine). Mycophenolate (or equivalent) dose and corticosteroid doses.</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count (WBC count) and routine biochemistry</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of glomerular filtration rate</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of graft function by measuring GFR</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications since last visit: Infections, rejection episodes, chronic graft dysfunction, other complications</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV prophylaxis, drug and dosage. Serious Adverse events related or no related to the drug</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up loss/death (if it occurs)</measure>
    <time_frame>up to 12 months from transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Cytomegalovirus</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CMV-positive (R+) lung transplant patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 18 years.

          -  Men or women who have received a lung transplant.

          -  CMV-seropositive patients (R+).

          -  Patients who have been informed of the study procedures and have signed the informed
             consent form.

          -  Over 3 months posttransplant.

        Exclusion Criteria:

          -  Patients who are not expected to be able to be followed during the first 12 months
             posttransplant.

          -  Patient participation in another clinical trial or study will not be a criterion for
             exclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Monforte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piedad Ussetti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susana Gómez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Vall d'Hebron Laboratory</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Monforte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebrón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piedad Ussetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Cifrián, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José M Borro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario A Coruña</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virginia Pérez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amparo Solé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor Monforte, MD</last_name>
    <phone>+34932746065</phone>
    <email>vmonforte@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Cifrían, MD</last_name>
      <email>jose492@separ.es</email>
    </contact>
    <investigator>
      <last_name>José Cifrián, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piedad Ussetti, MD</last_name>
      <email>pusetti.hpth@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Piedad Ussetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José M Borro, MD</last_name>
      <email>Jose.MA.Borro.Mate@sergas.es</email>
    </contact>
    <investigator>
      <last_name>José M Borro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Monforte, MD</last_name>
      <email>vmonforte@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Victor Monforte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Santos, MD</last_name>
      <email>fsantos1957@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Pérez, MD</last_name>
      <email>vluz71@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Virginia Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Solé, MD</last_name>
      <email>sole_amp@gva.es</email>
    </contact>
    <investigator>
      <last_name>Amparo Solé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Catalana de Pneumologia</investigator_affiliation>
    <investigator_full_name>Victor Monforte</investigator_full_name>
    <investigator_title>Hospital Vall d'Hebron</investigator_title>
  </responsible_party>
  <keyword>Lung transplant</keyword>
  <keyword>Quantiferon</keyword>
  <keyword>Immuknow</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
